Management of Apalutamide-Related Side Effects
Introduction to Apalutamide and Its Side Effects
- Apalutamide can cause nausea, with clinical trials showing an incidence rate of 18.1% compared to 15.8% in placebo groups, as observed in the pivotal SPARTAN trial 1
- The American Urological Association notes that nausea is not among the most severe or common side effects of apalutamide, with more common side effects including fatigue, hypertension, rash, and diarrhea 1
Assessment and Management of Nausea
- For patients experiencing nausea while on apalutamide, the National Comprehensive Cancer Network recommends assessing nausea by ruling out other causes and determining severity and impact on quality of life 2
- The National Comprehensive Cancer Network suggests that prophylactic antiemetics are recommended for patients with a prior history of medication-induced nausea, with first-line agents including dopamine receptor antagonists and benzodiazepines 2
- If nausea persists, the National Comprehensive Cancer Network recommends adding serotonin receptor antagonists and considering corticosteroids in combination with metoclopramide and ondansetron 2
Dosing Strategy and Persistent Nausea
- For persistent nausea, the National Comprehensive Cancer Network suggests switching from as-needed to scheduled antiemetics for one week, then reassessing 2
- If nausea persists beyond one week, the National Comprehensive Cancer Network recommends reassessing the cause and considering medication changes, including dose modification of apalutamide or switching to an alternative androgen receptor signaling inhibitor (enzalutamide or darolutamide) 3
Monitoring and Managing Other Side Effects
- Regular assessment of nausea and other gastrointestinal symptoms during follow-up visits is recommended, along with proactive management of other common side effects, including hypothyroidism (monitoring TSH, especially in the first 4-6 weeks) 4
- The National Comprehensive Cancer Network also recommends monitoring for fall risk and fracture prevention 4
Quality of Life and Treatment Discontinuation
- Despite side effects, studies have shown that health-related quality of life is generally maintained in patients receiving apalutamide, indicating that with proper management, patients can continue to benefit from this effective therapy while maintaining acceptable quality of life 4
- The overall discontinuation rate due to adverse events in the SPARTAN trial was 10.6% for apalutamide versus 7.0% for placebo, suggesting that most side effects, including nausea, can be managed without necessitating treatment discontinuation 1